A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

Sex: All

Ages: 18 Years – 70 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 54

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Location: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing Municipality

Summary

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage Intermediate/High-Risk extranodal NK/T cell lymphoma

Eligibility Criteria

Inclusion Criteria: * Biopsy proved extranodal NK/T cell lymphoma * No previous anti-cancer treatment * Measurable lesion on baseline PET/CT and MRI * Stage I-II * Have at lest one following risk factor: Elevated serum LDH level; PTI+; stage II * ECOG PS 0-1 * Sufficient organ functions Exclusion Criteria: * Other mature T- or NK- lymphoma * Hemophagocytic lymphohistiocytosis * Primary CNS lymphoma or CNS-involved lymphoma * History of malignancy except for cutaneous basal-/squamous- cell carcinoma or cervical carcinoma in situ 3 years prior to study treatment

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05254899). StuddyBuddy aggregates publicly available trial information.